000 03536nam a2200421 a 4500
003 MX-TeUDD
005 20240306161816.0
008 031016b2005 njuad gr 001 0 eng c
020 _a1588292002
020 _a9781588292001
040 _aMX-TeUDD
_bspa
_cMX-TeUDD
041 _aeng
050 0 4 _aRC271.C5
_bO4 2005
245 0 0 _aCombination cancer therapy :
_bmodulators and potentiators /
_cedición, Gary K. Schwartz.
246 2 _aModulators and potentiators.
260 _aTotowa, N.J. :
_bHumana,
_c2005
300 _a284 p. :
_bil., gráf. ;
_c23 cm.
490 0 _aCancer drug discovery and development
504 _aIncluye referencias bibliográficas.
505 2 _a1. Targeting of the EGFR as a modulator of cancer chemotherapy.-- 2. Cyclin-dependent kinase inhibitors in combination chemotherapy.-- 3. Development of protein kinase C and cyclin-dependent kinase inhibitors as potentiators of cytotoxic drug action in leukemia.-- 4. Carboxyamidotriazole, an inhibitor of nonvoltage-operated calcium entry: single-agent and combination therapy for ovarian carcinoma.-- 5. Targeted F-particle therapy: a rational approach to drug development in hematologic diseases and solid tumors.-- 6. Pharmacological modulation of fluoropyrimidines: building on the lessons of the past.-- 7. Development of inhibitors of HER2 with taxanes: new directions in breast cancer therapy.-- 8 Targeting NF-PB to increase the activity of cisplatin in solid tumors.-- 9. Combinations of chemotherapy and G3139, an antisense Bcl-2 oligonucleotide.-- 10. Use of animal models to evaluate signal transduction inhibitors as modulators of cytotoxic therapy.
520 2 _aExpert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.
526 8 _aSalud
650 0 _aDrug interactions.
_949258
650 4 _aApoptosis.
_949259
650 0 _aCancer
_xChemotherapy.
_981766
650 4 _aCáncer
_xQuimioterapia.
_910182
650 4 _aCáncer
_xTratamiento.
_981184
650 4 _aOncología.
_972284
650 4 _aMedicina.
_921519
700 1 _aSchwartz, Gary K.,
_eed.
_949263
856 _uhttps://web.archive.org/web/20240306235941/https://media.springernature.com/full/springer-static/cover-hires/book/978-1-59259-864-9?as=webp
_zPortada. (Wayback Machine, Internet Archive).
856 _uhttps://books.google.bj/books?id=4K0si9SvzRIC&printsec=frontcover&hl=es
_zGoogle Book.
856 _uhttps://web.archive.org/web/20240306235935/https://link.springer.com/book/10.1385/1592598641#toc
_zMás información. (Springer. / Wayback Machine, Internet Archive).
856 _uhttps://web.archive.org/web/20240307001045/https://link.springer.com/content/pdf/bfm:978-1-59259-864-9/1?pdf
_zTabla de contenido. (Wayback Machine, Internet Archive).
905 _aAcervo
906 _aRocio
_b20050823
942 _cBK01
_2lcc
999 _c269387
_d269387
907 _c1
_dAlejandro Alberto Castrejón Murillo